SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

30 Apr 2025 Evaluate
The March 2025 quarter revenue stood at Rs. 10139.40 millions, up 9.49% as compared to Rs. 9260.70 millions during the corresponding quarter last year.Modest increase of 18.89% in the Net Profit was reported from. 1626.90 millions to Rs. 1934.30  millions.Operating profit for the quarter ended March 2025 rose to 2675.80 millions as compared to 2608.30 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 10139.40 9260.70 9.49 43220.40 39711.20 8.84 43220.40 39711.20 8.84
Other Income 179.30 336.80 -46.76 1198.70 1164.80 2.91 1198.70 1164.80 2.91
PBIDT 2675.80 2608.30 2.59 13245.90 12359.10 7.18 13245.90 12359.10 7.18
Interest 6.70 14.20 -52.82 46.00 68.00 -32.35 46.00 68.00 -32.35
PBDT 2669.10 2594.10 2.89 13199.90 12291.10 7.39 13199.90 12291.10 7.39
Depreciation 387.60 334.70 15.81 1399.30 1321.60 5.88 1399.30 1321.60 5.88
PBT 2281.50 2259.40 0.98 11800.60 10969.50 7.58 11800.60 10969.50 7.58
TAX 347.20 632.50 -45.11 2631.70 2897.10 -9.16 2631.70 2897.10 -9.16
Deferred Tax -43.80 34.20 -228.07 51.40 121.30 -57.63 51.40 121.30 -57.63
PAT 1934.30 1626.90 18.89 9168.90 8072.40 13.58 9168.90 8072.40 13.58
Equity 250.70 252.70 -0.79 250.70 252.70 -0.79 250.70 252.70 -0.79
PBIDTM(%) 26.39 28.17 -6.30 30.65 31.12 -1.53 30.65 31.12 -1.53

Ajanta Pharma Share Price

2803.50 53.50 (1.95%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×